Excessive Apixaban Concentrations in a Bleeding Patient Treated With Pharmacological Reversal and Extracorporal Removal—A Case Report
In trauma, even therapeutic apixaban levels can significantly exacerbate bleeding. In cases of overdose, the risk of prolonged, life-threatening hemorrhage increases substantially, necessitating targeted interventions, such as pharmacological reversal agents. Rapid identification of elevated anticoagulant levels is crucial to initiate specific countermeasures and limit blood loss, and point-of-care testing may facilitate timely treatment. In our case of an extreme overdose of apixaban (max 5664.24 ng/mL, first report of such high amount) has resulted in serious and life-threatening clinical symptoms due to sustained multiple injuries. It is still a debate which therapies prove the most efficacious, whereby the vast surplus of apixaban and the short half-life of andexanet alfa must be considered. This case, in which high apixaban concentration persisted, might help to shed light on these issues.
Authors
- Richard F. Kraus (ORCID: https://orcid.org/0000-0001-5280-6530)
- Ralph Burkhardt (ORCID: https://orcid.org/0000-0003-1924-1202)
- Alexander Dejaco (ORCID: https://orcid.org/0000-0002-1985-2102)
- Martin G. Kees (ORCID: https://orcid.org/0000-0003-1708-0265)
- Michael Paal (ORCID: https://orcid.org/0000-0001-8831-0238)
- Johanna Rosenberger
- Christina Hart
Publication Details
- Journal
- University of Regensburg Publication Server (University of Regensburg)
- Published
- 2026-01-01
- DOI
- https://doi.org/10.5283/epub.79028
- Primary Topic
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Type
- article
- Field-Weighted Citation Impact
- 0.00